4-[4-[2-[(2R)-2-(3-氯苯基)-2-羟基乙基]氨基]乙基]苯基]-2-甲氧基苯甲酸苯甲酸 | 643094-49-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[4-[2-[(2R)-2-(3-氯苯基)-2-羟基乙基]氨基]乙基]苯基]-2-甲氧基苯甲酸苯甲酸
• 英文名称: Fasobegron
• 英文别名: 4-[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-2-methoxybenzoic acid
• CAS: 643094-49-9
• 化学式: C₂₄H₂₄ClNO₄
• 分子量: 425.9
• InChiKey: IBPCNRNTIRZRJZ-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Aminoalcohol derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040006143A1

  公开（公告）日：2004-01-08

  The present invention relates to a compound formula [I]: 1 wherein 2 Y is bond, —O—(CH 2 ) n — (in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R 1 is hydrogen, lower alkyl, etc., R 2 is hydrogen or an amino protective group, R 3 is hydrogen or lower alkyl, R 4 is hydrogen or lower alkyl, R 5 and R 8 are each independently hydrogen, halogen, hydroxy, lower alkyl, etc., R 6 is hydrogen, lower alkyl, etc., R 9 is hydrogen or lower alkyl, and i is 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

  本发明涉及一种化合物公式[I]: 1 其中 2 Y是键，—O—(CH 2 ) n — (其中n是1、2、3或4)，等等， Z是氰基，四唑基，等等， R 1 是氢，低级烷基，等等， R 2 是氢或氨基保护基团， R 3 是氢或低级烷基， R 4 是氢或低级烷基， R 5 和R 8 各自独立是氢，卤素，羟基，低级烷基，等等， R 6 是氢，低级烷基，等等， R 9 是氢或低级烷基，以及 i是1或2， 或其盐。本发明的化合物[I]及其药用可接受的盐对于预防性和/或治疗性治疗尿频或尿失禁是有用的。
• Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
  申请人：Serenity Pharmaceuticals, LLC

  公开号：US10568927B2

  公开（公告）日：2020-02-25

  The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.

  本发明提供了去氨加压素与β-3-肾上腺素能受体激动剂联合使用的方法和组合物。这些方法和组合物可用于治疗夜尿症和其他尿频疾病。
• METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3 ADRENERGIC RECEPTOR AGONIST
  申请人：ALLERGAN, INC.

  公开号：EP3024474A1

  公开（公告）日：2016-06-01
• METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WTIH A BETA-3-ADRENERGIC RECEPTOR AGONIST
  申请人：Allergan, Inc.

  公开号：US20150031613A1

  公开（公告）日：2015-01-29

  The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.
• METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3-ADRENERGIC RECEPTOR AGONIST
  申请人：Serenity Pharmaceuticals, LLC

  公开号：US20180289769A1

  公开（公告）日：2018-10-11

  The invention provides methods and compositions for use of desmopressin in combination with a beta- 3 -adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.